Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
131. |
ECCT/16/08/01 | A5349/TBTC S31 A5349/TBTC S31 “Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: A randomized, open-label, controlled phase 3 clinical trial” |
Principal Investigator(s) 1. Abraham Mosigisi Siika Site(s) in Kenya 1. Moi University Clinical Research Centre (Uasin Gishu county) 2. KEMRI Walter Reed Project (Kericho county) |
13-12-2016 |
View |
132. |
ECCT/16/08/02 | Zeenk study Zeenk Acceptability Study |
Principal Investigator(s) 1. Margaret Oluka 2. David Kimutai 3. Caren Emadu Site(s) in Kenya 1. Mbagathi District Hospital (Nairobi City county) 2. Mama Lucy Kibaki Hospital (Nairobi City county) |
10-08-2016 |
View |
133. |
ECCT/16/08/03 | IMPAACT 2001 A Phase I/II Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-infected and HIV-1-uninfected Pregnant and Postpartum Women with Latent Tuberculosis Infection |
Principal Investigator(s) 1. Deborah Chepngeno Langat Site(s) in Kenya Kenya Medical Research Institute Walter Reed project |
27-10-2016 |
View |
134. |
ECCT/16/09/02 | Monitoring Pre-Exposure Prophylaxis for Young Adult Women ( (MPYA) Next generation real-time monitoring for PrEP adherence in young adult women. |
Principal Investigator(s) 1. Prof. Elizabeth Anne Bukusi Bukusi 2. Dr. Stella Njuguna Njuguna Site(s) in Kenya 1. KISUMU SITE (Kisumu county) |
27-09-2016 |
View |
135. |
ECCT/16/09/03 | Effect of Schistosoma mansoni infection on incidence of Plasmodium falciparum malaria among 1-5 year old children in western Kenya. Effect of Schistosoma mansoni infection on incidence of Plasmodium falciparum malaria among 1-5 year old children in western Kenya. |
Principal Investigator(s) 1. Dr.Pauline NM Mwinzi Site(s) in Kenya KEMRI CGHR |
28-11-2016 |
View |
136. |
ECCT/16/10/01 | INVICTUS INVESTIGATION OF RHEUMATIC AF TREATMENT USING VITAMIN K ANTAGONISTS, RIVAROXABAN OR ASPRIN STUDIES |
Principal Investigator(s) 1. Elijah Nyainda Ogola 2. felix ayub barasa Site(s) in Kenya 1. Kenyatta National hospital (Nairobi City county) 2. Moi teaching and Referral Hospital (Uasin Gishu county) 3. The Karen Hospital (Nairobi City county) |
07-03-2017 |
View |
137. |
ECCT/16/10/02 | PAINT Study A Phase II, open label, single arm trial to evaluate the pharmacokinetics, safety, tolerability, and antiviral activity of rilpivirine (TMC278) in antiretroviral-naïve HIV-1 infected adolescents and children aged ≥6 to <18 years |
Principal Investigator(s) 1. Professor Walter Jaoko Site(s) in Kenya 1. KAVI Institute of Clinical Research (Nairobi City county) 2. Kenya Medical Research Institute/Walter Reed Project, HIV Program (Kericho county) |
13-02-2017 |
View |
138. |
ECCT/16/11/02 | IMPAACT P1093 Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and AdolescentsPhase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents |
Principal Investigator(s) 1. Lucy Koech Site(s) in Kenya KENYA MEDICAL RESEARCH INSTITUTE/WALTER REED PROJECT HIV PROGRAME |
28-03-2017 |
View |
139. |
ECCT/16/11/03 | COAST Childrens Oxygen Administration Strategies Trial |
Principal Investigator(s) 1. Kathryn Maitland Site(s) in Kenya 1. Kilifi County Hospital (Kilifi county) 2. Coast Provincial General Hospital (Mombasa county) |
22-02-2017 |
View |
140. |
ECCT/16/11/04 | RV456 A Randomized, Observer-blind, Placebo-controlled, Two part, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo |
Principal Investigator(s) 1. JANET OYIEKO Site(s) in Kenya KOMBEWA CLINICAL RESEARCH CENTRE |
28-01-2017 |
View |